These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32998960)

  • 1. Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy.
    Carrato C; Alameda F; Esteve-Codina A; Pineda E; Arpí O; Martinez-García M; Mallo M; Gut M; Lopez-Martos R; Barco SD; Ribalta T; Capellades J; Puig J; Gallego O; Mesia C; Muñoz-Marmol AM; Archilla I; Arumí M; Blanc JM; Bellosillo B; Menendez S; Esteve A; Bagué S; Hernandez A; Craven-Bartle J; Fuentes R; Vidal N; Aldecoa I; Iglesia N; Balana C
    Clin Cancer Res; 2020 Dec; 26(24):6600-6609. PubMed ID: 32998960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA sequencing and Immunohistochemistry Reveal
    Esteve-Codina A; Alameda F; Carrato C; Pineda E; Arpí O; Martinez-García M; Mallo M; Gut M; Dabad M; Tortosa A; Del Barco S; Capellades J; Puig J; Gallego O; Pujol T; Oleaga L; Gil-Gil M; de Quintana-Schmidt C; Valduvieco I; Martinez-Cardús A; Bellosillo B; Muñoz-Marmol AM; Esteve A; Domenech M; Camins A; Craven-Bartle J; Villa S; Marruecos J; Domenech S; de la Iglesia N; Balana C
    Clin Cancer Res; 2021 Jan; 27(2):645-655. PubMed ID: 33106291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simplified integrated molecular and immunohistochemistry-based algorithm allows high accuracy prediction of glioblastoma transcriptional subtypes.
    Orzan F; Pagani F; Cominelli M; Triggiani L; Calza S; De Bacco F; Medicina D; Balzarini P; Panciani PP; Liserre R; Buglione M; Fontanella MM; Medico E; Galli R; Isella C; Boccaccio C; Poliani PL;
    Lab Invest; 2020 Oct; 100(10):1330-1344. PubMed ID: 32404931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas.
    Doucette T; Rao G; Rao A; Shen L; Aldape K; Wei J; Dziurzynski K; Gilbert M; Heimberger AB
    Cancer Immunol Res; 2013 Aug; 1(2):112-22. PubMed ID: 24409449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes of glioblastoma.
    Zhang JX; Zhang J; Yan W; Wang YY; Han L; Yue X; Liu N; You YP; Jiang T; Pu PY; Kang CS
    Neuro Oncol; 2013 Mar; 15(3):279-89. PubMed ID: 23295773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma.
    Cheng W; Zhang C; Ren X; Jiang Y; Han S; Liu Y; Cai J; Li M; Wang K; Liu Y; Hu H; Li Q; Yang P; Bao Z; Wu A
    J Neurosurg; 2017 Jan; 126(1):249-259. PubMed ID: 26967788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma.
    Gill BJ; Pisapia DJ; Malone HR; Goldstein H; Lei L; Sonabend A; Yun J; Samanamud J; Sims JS; Banu M; Dovas A; Teich AF; Sheth SA; McKhann GM; Sisti MB; Bruce JN; Sims PA; Canoll P
    Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12550-5. PubMed ID: 25114226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
    Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
    Front Immunol; 2022; 13():773264. PubMed ID: 35185876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Subgroups of Glioblastoma- an Assessment by Immunohistochemical Markers.
    Nagy Á; Garzuly F; Padányi G; Szűcs I; Feldmann Á; Murnyák B; Hortobágyi T; Kálmán B
    Pathol Oncol Res; 2019 Jan; 25(1):21-31. PubMed ID: 28948518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry.
    Popova SN; Bergqvist M; Dimberg A; Edqvist PH; Ekman S; Hesselager G; Ponten F; Smits A; Sooman L; Alafuzoff I
    Histopathology; 2014 Feb; 64(3):365-79. PubMed ID: 24410805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Key Pathways and Genes in the Orai2 Mediated Classical and Mesenchymal Subtype of Glioblastoma by Bioinformatic Analyses.
    Yuan F; Yi L; Hai L; Wang Y; Yang Y; Li T; Tong L; Ma H; Liu P; Ming H; Ren B; Yu S; Lin Y; Yang X
    Dis Markers; 2019; 2019():7049294. PubMed ID: 31772693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma.
    Park AK; Kim P; Ballester LY; Esquenazi Y; Zhao Z
    Neuro Oncol; 2019 Jan; 21(1):59-70. PubMed ID: 30053126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesenchymal and Proneural Subtypes of Glioblastoma Disclose Branching Based on GSC Associated Signature.
    Steponaitis G; Tamasauskas A
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
    Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
    J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
    Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.
    Pratt D; Dominah G; Lobel G; Obungu A; Lynes J; Sanchez V; Adamstein N; Wang X; Edwards NA; Wu T; Maric D; Giles AJ; Gilbert MR; Quezado M; Nduom EK
    Neurosurgery; 2019 Aug; 85(2):280-289. PubMed ID: 30011045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
    Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
    Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular heterogeneity of glioblastomas: does location matter?
    Denicolaï E; Tabouret E; Colin C; Metellus P; Nanni I; Boucard C; Tchoghandjian A; Meyronet D; Baeza-Kallee N; Chinot O; Figarella-Branger D
    Oncotarget; 2016 Jan; 7(1):902-13. PubMed ID: 26637806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
    Patil V; Mahalingam K
    Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.